Evercore ISI lowered the firm’s price target on Jasper Therapeutics (JSPR) to $7 from $12 and keeps an Outperform rating on the shares. The firm adjusted targets for its small-to-mid cap biotechnology coverage as it analyzed Q2 catalysts. However, the firm acknowledges that stocks in the group are moving on longer-horizon theses so it also looked at all FY26 catalysts, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JSPR:
- Jasper Therapeutics’ Deep Cuts May Backfire: Analyst Warns Downsizing Could Undermine Briquilimab Strategy and Cash Runway
- Buy Rating on Jasper: Briquilimab’s Strong CSU Efficacy, Favorable Safety, and Competitive Profile Underpin Key Near‑Term Value Driver
- Jasper Therapeutics reports Q4 EPS (32c), consensus (82c)
- Jasper Therapeutics assumed with a Neutral at UBS
- Jasper Therapeutics, Inc. (JSPR) Q4 Earnings Cheat Sheet